Elacestrant dihydrochloride

DRUG2 trials

Sponsors

Carrick Therapeutics Limited, Stemline Therapeutics, Inc.

Conditions

Breast CancerHepatic ImpairmentLocally Advanced Breast CancerMetastatic Breast Cancer

Phase 1

A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

CompletedNCT05963997

Carrick Therapeutics LimitedBreast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer

Start: 2023-10-09End: 2026-03-06Updated: 2026-03-23

A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

CompletedNCT06126575

Stemline Therapeutics, Inc.Hepatic Impairment

Start: 2023-03-13End: 2024-11-11Updated: 2024-11-19

Related Papers

Abstract P2-07-22: Cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib combined with selective estrogen receptor degrader (SERD) elacestrant in advanced HR+ breast cancer after CDK4/6i: dose escalation data from the Phase 1b/2 SUMIT-ELA study

Clinical Cancer Research2025-06-13